Intervention

Lymphodepleting chemotherapy

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting5

Common conditions10

Lead sponsors shown1

Clinical trials

5 shown

Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)NCT07744256 · 2026-03-02

Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLCNCT07641023 · 2026-03-02

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)NCT07486089 · 2026-02-02

Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)NCT07480213 · 2026-02-02

Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLCNCT07467863 · 2026-02-02

Common conditions

Non-Small Cell Lung Cancer2 Relapsed/Refractory SCLC2 Small Cell Lung Cancer (SCLC)2 Advanced/Metastatic1 Advanced/Metastatic NSCLC1 Breast Cancer (Locally Advanced or Metastatic)1 Extensive-stage SCLC1 HER2-positive Breast Cancer1 SCLC, Extensive Stage1 Triple-Negative Breast Cancer (TNBC)1

Leading sponsors

Beijing Biotech5

Trial status mix

RECRUITING5

Phase mix

PHASE15

PHASE25

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.